retatrutide nash nonalcoholic fatty liver disease trial Researchers report promising results with retatrutide, which significantly reduced fat in some patients over several months. Excess liver fat causes metabolic dysfunction–associated steatotic China Catalogue peptide Retatrutide Obesity

Structure Therapeutics and AstraZeneca each shared mid-stage data from their respective GLP-1 pills

Explore detailed information about tirzepatide treatment

Adding insulin to non-insulin antihyperglycemic agents may result in better glycemic levels with a lower dose of insulin [74], and may induce less weight gain and less hypoglycemia than that seen when non-insulin antihyperglycemic agents are stopped and insulin is used alone [75,76]

AMPK stacking with other AMPK activators

The highest retatrutide dose produced the biggest number in the Phase 3 TRIUMPH-1 trial: an average body-weight reduction of 28.3% at 80 weeks